Verastem,Inc. (NASDAQ:VSTM) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07. Submission of Matters to a Vote of Security Holders.
The Annual Meeting of Stockholders of Verastem,Inc. was held in
Needham, Massachusetts on May17, 2017. At that meeting, the
stockholders considered and acted upon the following proposals:
1. Election of ClassII Directors. By the vote reflected
below, the stockholders elected the following individuals to
serve as ClassII directors until the 2020 Annual Meeting of
Stockholders and until their respective successors are duly
elected and qualified:
|
|
VotesFor |
|
VotesWithheld |
|
BrokerNon- Votes |
|
|
|
Timothy Barberich |
10,485,633 |
5,630,263 |
12,058,096 |
||||
|
Alison Lawton |
15,343,873 |
772,023 |
12,058,096 |
There were no abstentions with respect to this proposal.
2. The Ratification of the Selection of Ernst Young LLP as
Verastem,Inc.s Independent Registered Public Accounting Firm for
the Current Fiscal Year. The stockholders voted to ratify
the selection of Ernst Young LLP as Verastem,Inc.s independent
registered public accounting firm for the current fiscal year.
28,046,675 shares voted for the proposal; 88,401 shares voted
against the proposal; and 38,916 shares abstained from voting on
the proposal. There were no broker non-votes on the proposal.
About Verastem, Inc. (NASDAQ:VSTM)
Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company’s programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company’s VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company’s VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers. Verastem, Inc. (NASDAQ:VSTM) Recent Trading Information
Verastem, Inc. (NASDAQ:VSTM) closed its last trading session down -0.08 at 2.40 with 402,332 shares trading hands.
